Notably, it seems that lactadherin contributes to tumor progression [41–45]⁠, promotes survival of tumor cells [46, 47]⁠, induces epithelial-mesenchymal transition (EMT) [48–50]⁠, and promotes angiogenesis [51, 52]⁠ and metastasis [43, 45, 53]⁠, which has positioned lactadherin as an interesting possible prognostic biomarker and therapeutic target for BC. The gene discussed is MFGE8; the disease is neoplasm.